appili therapeutics infoappilitherapeutics ext    appili therapeutics employment opportunities – appili therapeutics infoappilitherapeutics ext    appili therapeutics employment opportunities available positions below is a list of positions that are available with appili therapeutics no positions currently available thank you for your interest in appili therapeutics  all positions are currently filled if you wish to be considered for any future openings please send a detailed cv and cover letter to careersappilitherapeuticscom send us your resume pipeline – appili therapeutics infoappilitherapeutics ext    appili therapeutics pipeline pipeline appili therapeutics is currently leading several antiinfective programs at various stages of development these programs are designed to address the existing critical unmet medical needs of patients with infectious disease providing novel therapeutics to treat even the most drugresistant infections gram negative programantibiotic repurposing gram negative program appili is developing a small molecule antibiotic to treat nosocomial infections caused by drugresistant gramnegative bacteria the antibiotic ati inhibits bacterial translation by binding to the s ribosomal subunit it has a unique binding site and mechanism of action representing a novel class of antibiotic antibiotic repurposing appili is repurposing an existing antibiotic through the fda’s b new drug application process an appealing regulatory strategy that helps avoid unnecessary duplication of studies already performed on the previously approved drug this antibiotic ati will address an identified unmet medical need the program is currently confidential with the target and program details to be announced upon entering the clinic in early  previous slide next slide strategy – appili therapeutics infoappilitherapeutics ext    appili therapeutics strategy focus our primary focus is the development of therapeutics to treat infectious disease that provide “differentiated benefits” to patients we are actively seeking innovative solutions that target infectious disease with a particular focus on agents that address the rising concern of multidrug resistant bacteria with resources and experts available to analyse and develop promising antiinfective therapeutic programs we are interested in developing novel solutions to the current crises of infectious disease irrespective of disease method of delivery and stage of development favorable regulatory environment the gain act improvements to the regulatory environment priority review voucher program recent regulatory changes have incentivized the development of antiinfective agents to increase commercialization the generating antibiotics incentives now act gain act grants an additional five years of market exclusivity as well as a streamlined process for priority review by the fda the neglected tropical disease voucher program is an incentive for companies to invest in new drugs for the treatment of neglected tropical diseases through the award of a transferable “priority review vouchers” a priority review voucher can be applied to any drug development program and typically reduces the time for the fda to review a new drug application to as little as six months the generating antibiotics incentives now gain act which came into effect on october   provides a favorable environment for the development of new antibiotics under gain a qualified infectious disease product qidp is a new “antibacterial or antifungal drug for human use intended to treat serious or lifethreatening infections including those caused by an antibacterial or antifungal resistant pathogen including novel or emerging infectious pathogens” under the act sponsors developing qidps may benefit from the following incentives market exclusivity qidps would be issued five years of market exclusivity in addition to the periods of exclusivity for which they would otherwise qualify in the us new small molecule drugs are granted five years of hatch waxman market exclusivity so this provision would provide a total of ten years of market exclusivity regardless of patent position priority review qidps would qualify for priority review by the fda which would cut the time to approval to six months fast track review sponsors of qidps would be provided with early and frequent communications with the fda in addition to the typical review opportunities updated guidance the gain act provides a specific timetable for the fda to develop and issue final guidance on how to conduct antibiotics trials pathogen focused drug development the fda will issue guidance on pathogenfocused antibacterial drug development rather than diseasefocused development that currently exists priority review vouchers prv came into effect in  with the first voucher issued in  under the law a developer of a treatment for a neglected or rare pediatric disease receives a voucher for priority review from the fda to be used with a product of its choice prvs may also be sold to other pharmaceutical companies to improve the return on investment in areas of drug development that previously struggled from a lack of innovation due to more challenging markets the first three sales of prvs are detailed below the first sale of its kind biomarin sold their prv to sanofi and regeneron for m august  knight therapeutics was awarded a prv upon the approval of impavido developed to treat leishmaniasis this voucher was sold for m to gilead sciences november  retrophin will receive a total of m from sanofi in exchange for their prv may   favorable regulatory environment recent regulatory changes have incentivized the development of antiinfective agents to increase commercialization the generating antibiotics incentives now act gain act grants an additional five years of market exclusivity as well as a streamlined process for priority review by the fda the neglected tropical disease voucher program is an incentive for companies to invest in new drugs for the treatment of neglected tropical diseases through the award of a transferable “priority review vouchers” a priority review voucher can be applied to any drug development program and typically reduces the time for the fda to review a new drug application to as little as six months  the gain act improvements to the regulatory environment the generating antibiotics incentives now gain act which came into effect on october   provides a favorable environment for the development of new antibiotics under gain a qualified infectious disease product qidp is a new “antibacterial or antifungal drug for human use intended to treat serious or lifethreatening infections including those caused by an antibacterial or antifungal resistant pathogen including novel or emerging infectious pathogens” under the act sponsors developing qidps may benefit from the following incentives market exclusivity qidps would be issued five years of market exclusivity in addition to the periods of exclusivity for which they would otherwise qualify in the us new small molecule drugs are granted five years of hatch waxman market exclusivity so this provision would provide a total of ten years of market exclusivity regardless of patent position priority review qidps would qualify for priority review by the fda which would cut the time to approval to six months fast track review sponsors of qidps would be provided with early and frequent communications with the fda in addition to the typical review opportunities updated guidance the gain act provides a specific timetable for the fda to develop and issue final guidance on how to conduct antibiotics trials pathogen focused drug development the fda will issue guidance on pathogenfocused antibacterial drug development rather than diseasefocused development that currently exists  priority review voucher program priority review vouchers prv came into effect in  with the first voucher issued in  under the law a developer of a treatment for a neglected or rare pediatric disease receives a voucher for priority review from the fda to be used with a product of its choice prvs may also be sold to other pharmaceutical companies to improve the return on investment in areas of drug development that previously struggled from a lack of innovation due to more challenging markets the first three sales of prvs are detailed below the first sale of its kind biomarin sold their prv to sanofi and regeneron for m august  knight therapeutics was awarded a prv upon the approval of impavido developed to treat leishmaniasis this voucher was sold for m to gilead sciences november  retrophin will receive a total of m from sanofi in exchange for their prv may  contact – appili therapeutics infoappilitherapeutics ext    appili therapeutics contact head office address  summer street halifax ns bh a phone number  ext  email  infoappilitherapeuticscom location send us a message name  email  telephone message  send messageclear toronto office address jlabs  toronto  university ave suite  toronto on mg l phone number  ext  email  infoappilitherapeuticscom location news – appili therapeutics infoappilitherapeutics ext    appili therapeutics news date name descasc appili therapeutics inc appoints pharmaceutical executive sean mcbride as vice president business development july   – halifax nova scotia –– appili therapeutics inc “appili” an antiinfective drug development company announced today that sean mcbride a  year pharmaceutical veteran has joined the company as vice president business development mr mcbride will lead appili’s outlicensing product inlicensing and acquisition opportunities as the company builds its pipeline of infectious disease products details july  newsby admin appili therapeutics to present at the bloom burton  co healthcare investor conference april   – halifax nova scotia –– appili therapeutics inc “appili” an antiinfective drug development company today announced that it will participate in this year’s bloom burton  co healthcare investor conference in toronto canada the event takes place may   at the sheraton centre toronto hotel details april  newsby admin appili therapeutics receives funding from the government of canada to support development of new antibiotic to treat gramnegative infections april   – halifax nova scotia –– appili therapeutics inc “appili” an antiinfective drug development company announced today that it will be receiving an additional  from the national research council of canada industrial research assistance program nrcirap bringing irap support for this project to a total of up to  this funding supports the development of ati an antibiotic targeting drugresistant gramnegative bacteria superbugs that cause potentially deadly infections details april  newsby admin appili therapeutics awarded m from acoa to fund clinical trials february   – halifax nova scotia –– appili therapeutics inc“appili” an antiinfective drug development company announced today that it will be receiving  from the atlantic canada opportunities agency acoa under the atlantic innovation fund aif this funding will enable appili to take its first drug ati – a tastemasked oral antibiotic that treats anaerobic infections like clostridium difficile – through clinical trials to be ready for market approval details february  newsby admin appili therapeutics inc appoints industry veteran stephen nicolle to its board for immediate release january   – halifax nova scotia –– appili therapeutics inc “appili” an antiinfective drug development company announced today that stephen nicolle has been appointed to its board of directors a seasoned executive mr nicolle has led companies to deliver innovative customer value and returned over  million to their investors details january  newsby admin appili therapeutics raises m in equity capital to develop its antiinfective pipeline december   – halifax nova scotia –– appili therapeutics inc “appili” an antiinfective drug development company announced today it raised  in its oversubscribed private placement financing participants in this capital raise included current appili investors such as innovacorp as well as new individual and institutional investors proceeds from the financing will be used… details december  newsby admin appili therapeutics inc appoints kimberly stephens as chief financial officer october   – halifax nova scotia –– appili therapeutics inc an antiinfective pharmaceutical development company announced today that kimberly stephens cpa has joined the company as chief financial officer ms stephens will be providing key financial and operational leadership to appili to help drive its growth details october  newsby admin appili raises m in seed round to develop novel antibiotics may   – halifax nova scotia –– appili therapeutics inc an antiinfective pharmaceutical development company announced today it has raised  to advance the research and development of its antiinfective drug candidates and open a medicinal chemistry lab in halifax   “completing this seed round of investment provides us with a solid base from… details may  newsby admin appili receives orphan drug designation from fda for ati treating c difficile in children halifax nova scotia – april   – appili therapeutics inc an antiinfective pharmaceutical development company announced today that the us food and drug administration fda has granted orphan drug designation for ati a tastemasked reformulation of metronidazole with the potential to effectively treat clostridium difficile infection cdi in children cdi is one of the… details april  newsby admin recent news check this page for recent news from appili therapeutics for more information about appili therapeutics please contact us at infoappilitherapeuticscom or through our contact page board of directors – appili therapeutics infoappilitherapeutics ext    appili therapeutics board of directors brian bloom chair brian bloom is a cofounder of bloom burton  co and serves as the firm’s chairman and chief executive officer by forging unique relationships with international healthcarespecialized investors brian raises capital for canadian healthcare companies while helping investors realize returns brian is a member of the life sciences advisory board at the national research council of canada and also serves on the board of directors at biotecanada the baycrest foundation brian is also the chairman of the board of triumvira immunologics appili therapeutics and grey wolf animal health and on the board of directors of qing bile therapeutics before cofounding bloom burton in  brian spent six years at dundee securities in the healthcare and biotechnology institutional sales and equity research groups brian started his career at new yorkbased investment banking firms sco financial group and molecular securities brian received an honors bachelor of science in biochemistry from mcmaster university and subsequently studied at the mount sinai graduate school for biological sciences of new york university with a focus in molecular endocrinology and biophysics john holyoake dphil member john holyoake vice president investment banking joined bloom burton  co in january  at bloom burton john’s responsibilities include ma advisory and monetization planning as well as conducting technical and commercial due diligence of companies across all healthcare sectors john’s area of expertise spans earlystage technologies to profitable healthcare service companies with a particular focus on preclinicalstage biotech john has previous industry experience with the clinical stage oncology company tenx biopharma and the life science consulting group shi link as well as with several earlystage life science companies he currently serves on the board of directors of triumvira immunologics and appili therapeutics john holds a master’s in biochemistry and doctorate from the university of oxford and made the transition across the atlantic for a postdoctoral research fellowship at the hospital for sick children toronto kevin sullivan mba member mr sullivan has over  years of experience working with early stage biotechnology companies and has raised over m in private equity and nondilutive government funding in biotechnology most recently he was chief executive officer at denovamed inc a biotechnology company focused on development of gramnegative and grampositive antibiotics previously he was chief operating officer at viron therapeutics a biopharmaceutical company developing a novel immunotherapy and recipient of the prix galien award for biotechnology at viron he and his team completed development of the company’s lead program through phase  clinical development with series a and b financing from a syndicate of international venture capital including two pharmaventure participants he is an active mentor and volunteer advisor for several startup biotechnology companies mr sullivan received a bsc in immunology from dalhousie university a graduate certificate in biotechnology from mcgill university and an mba from western university dr lidija marusic member dr lidija marusic is an investment manager at innovacorp a venture capital fund investing in seed and earlystage technology companies with over  years of experience in life science technology commercialization lidija manages all aspects of the investment due diligence approval and closing cycle and works handson with innovacorp’s portfolio companies prior to joining innovacorp lidija worked at mds capital corp now lumira capital and its seed fund medinnova partners inc focusing on commercializing biomedical discoveries lidija holds a doctor of medicine degree from the university of zagreb a phd in molecular genetics from the international school for advanced studies sissaisas and an mba from mcmaster university she served on the international peer review panel for the canadian networks of centres of excellence nce and on the proof of principle peer review committee of the canadian institutes for health research cihr lidija is a member of the board of directors for decell technologies inc dgi clinical inc and denovamed inc and a board observer at abk biomedical inc and densitas inc stephen nicolle member mr nicolle has  years of experience leading companies and growing shareholder value  he is currently president of cape bear advisors where he consults and holds numerous board positions including vice chair of the startup accelerator propel ict mr nicolle is the former ceo of leading healthcare technology company sti technologies where he negotiated agreements with top pharmaceutical companies resulting in an increase in revenue of  per cent  before sti technologies mr nicolle spent  years leading venturebacked technology companies including ceo of tatara systems ceo of sigma systems coo at march networks and president of nortel’s service provider ebusiness solutions group he is a graduate of western university with an honours degree in computer science management – appili therapeutics infoappilitherapeutics ext    appili therapeutics management kevin sullivan mba chief executive officer mr sullivan has over  years of experience working with early stage biotechnology companies and has raised over m in private equity and nondilutive government funding in biotechnology most recently he was chief executive officer at denovamed inc a biotechnology company focused on development of gramnegative and grampositive antibiotics previously he was chief operating officer at viron therapeutics a biopharmaceutical company developing a novel immunotherapy and recipient of the prix galien award for biotechnology at viron he and his team completed development of the company’s lead program through phase  clinical development with series a and b financing from a syndicate of international venture capital including two pharmaventure participants he is an active mentor and volunteer advisor for several startup biotechnology companies mr sullivan received a bsc in immunology from dalhousie university a graduate certificate in biotechnology from mcgill university and an mba from western university kimberly stephens chief financial officer ms stephens brings over  years of financial management experience and senior financial positions with private and public companies most recently she served as cfo of immunovaccine inc tsx imv otcqx immvf from  where she managed the raising of more than  million through equity financings and government grants prior to joining immunovaccine inc ms stephens served as director of finance for the canadian subsidiary of germanischer lloyd  she has also been the director of finance for solutioninc and started her career as an audit manager in the assurance and advisory group at pwc  ms stephens holds a bachelor of commerce degree from mount allison university and is a chartered professional accountant cpa jamie doran msc dabt ert vice president drug development ms doran has over  years experience as a regulatory toxicologist she has broad experience in the development monitoring and evaluation of nonclinical studies designed to test the safety metabolism and distribution of new products pharmaceuticals and chemicals entering international markets ms doran has managed and prepared preind ind and cta submissions to the us fda and health canada as well as successfully managed preclinical and clinical programs in various indications sean mcbride  vice president business development mr mcbride has over  years of experience in pharmaceutical and biotech commercialization pricing and business development in his role at appili therapeutics mr mcbride is responsible for all outlicensing activities as well as leading product inlicensing and acquisition opportunities to further enhance the company’s global business mr mcbride most recently served as commercial and business development lead at glaxosmithkline inc gsk leading a portfolio of assets valued at m at gsk he was involved in all aspects of business development from lead generation to integration and divestment including successfully completing numerous transactions with multinational pharmaceutical companies prior to joining gsk mr mcbride served as a director for healthcare agencies conducting commercial and strategic assessments in both canada and the us and also served as director of marketing with roche pharmaceuticals mr mcbride holds a bachelor of business administration degree from simon fraser university and is an active member of the canadian healthcare licensing association chla appili therapeutics inc company profile  bloomberg feedback appili therapeutics inc private company company profile sector health care industry biotech  pharma subindustry specialty pharma appili therapeutics inc operates a biopharmaceutical company the company develops therapies to enhance treatment outcomes by optimizing and improving the administration and tolerability of drug therapies appili therapeutics serves customers in canada corporate information address  summer street suite  halifax ns bh a canada phone  fax  web url wwwappilitherapeuticscom board members board members company stephen nicolle sti technologies ltd from the web key executives kevin sullivan ceoinvestor relations kimberly stephens chief financial officer sean mcbride vice presidentbusiness dev sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data appili therapeutics inc appoints pharmaceutical executive sean mcbride as vice president business developmenthomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoretry yahoo finance on firefox »yahoosearchsearchsign inus markets open in  hrs  minssp futures dow futures appili therapeutics inc appoints pharmaceutical executive sean mcbride as vice president business developmentbusiness wirejuly  reblogsharetweetsharehalifax nova scotiabusiness wireappili therapeutics inc “appili” an antiinfective drug development company announced today that sean mcbride a  year pharmaceutical veteran has joined the company as vice president business development mr mcbride will lead appili’s outlicensing product inlicensing and acquisition opportunities as the company builds its pipeline of infectious disease productswe are delighted to have mr mcbride join our strong leadership team” said kevin sullivan ceo of appili therapeutics “sean’s experience in international dealmaking along with his expertise in pharmaceutical sales and marketing will be invaluable as we build our balancedrisk pipeline of neartorevenue opportunities with higherrisk transformational drugs that can truly change the way we treat infectious disease”“this is an exciting time to be joining the appili team as it seeks to take advantage of the many incentives aimed at fighting antibiotic resistance and grow its pipeline of antiinfectives” said mr mcbride “there are many players including government nonprofit and forprofit organizations with an interest in infectious diseases and i look forward to bringing my experience working with these organizations and contributing to the company’s future success”mr mcbride brings more than two decades of experience within the canadian pharmaceutical and biotechnology industry his expertise lies in licensing purchasing and divesting assets in addition to advancing the commercialization of early stage assets and identifying opportunities for growth prior to joining appili mr mcbride spent  years at glaxosmithkline inc gsk serving in many roles of increasing responsibility most recently he served as head of an entrepreneurial business unit where he negotiated global asset transactions and was responsible for the commercial success of over  brand assets prior to joining gsk mr mcbride served as a director for healthcare agencies conducting commercial and strategic assessments in both canada and the us and also served as director of marketing with roche pharmaceuticals mr mcbride has a bachelor of business administration from simon fraser universityabout appili therapeuticsappili is dedicated to identifying acquiring and advancing novel therapeutics for infectious disease the company has two antiinfective programs ati and ati in its pipeline ati is a tastemasked treatment for anaerobic infections that has been granted orphan drug status by the fda appili plans to take ati into clinical trials in  appili’s second product ati is a novel antibiotic with broad potential to treat deadly gramnegative infections these drugresistant infections have been identified by the us centers for disease control cdc and the world health organization as posing the highest threat to human health for more information visit wwwappilitherapeuticscomview source version on businesswirecom httpwwwbusinesswirecomnewshomeenreblogsharetweetsharerecently viewedyour list is emptywhat to read nextcreepy fruitfly surveillance malware hits american apple macsforbeswomen everywhere should carry this tiny devicesiren songsponsoredswaziland halves worlds highest hiv infection rate reportafpdrugs cocktail cut hiv deaths by bbc newsconservative media outlets are sending trump a big warning on jeff sessions — and trump is paying attentionbusiness insiderengineer finds pattern makes millions in stocksmoney morningsponsoredchinas army looks like its getting ready for something big to go down in north koreabusiness insiderheres trumps approval rating in every statebusiness insidereconomists answer are we at full employmentyahoo finance videoa pennycrypto miracle making some americans richagora financialsponsoredfacebook earnings fed announcement — what you need to know in markets on wednesdayyahoo financedonald trump thinks jeff bezos is his biggest threatyahoo financesenate opens obamacare debate at last but outcome in doubtassociated pressstart earning miles with the best travel cardwise breadsponsoredus navy releases video showing close call and machinegun firing near an iranian patrol boatbusiness insiderformer obama official weighs in on trumps plan to bring back manufacturing jobsyahoo finance videous energy secretary duped into fake interview with russian comediansbob hope theyre proud of themselves how hard is it to prank a moronjoin the conversation   appili therapeutics inc private company information  bloomberg july    am et biotechnology company overview of appili therapeutics inc snapshot people company overview appili therapeutics inc develops therapeutic agents for the treatment of infectious diseases the company develops classes of antibiotics and antiinfectives to the clinic to improve treatment and health of patients suffering from infection its products under pipeline are gram negative program where it develops a small molecule antibiotic to treat nosocomial infections caused by drugresistant gramnegative bacteria and ati an antibiotic that addresses identified medical needs through repurposing an existing antibiotic the company is headquartered in halifax canada  summer streetsuite halifax ns bh acanada phone  wwwappilitherapeuticscom key executives for appili therapeutics inc mr kevin sullivan bsch mba chief executive officer and director ms kimberly stephens cpa chief financial officer ms jamie doran mscdabtert vice president of drug development mr sean mcbride vice president of business development compensation as of fiscal year  appili therapeutics inc key developments appili therapeutics inc names sean mcbride as vice president business development jul   appili therapeutics inc announced that sean mcbride a  year pharmaceutical veteran has joined the company as vice president business development mr mcbride will lead appili’s outlicensing product inlicensing and acquisition opportunities as the company builds its pipeline of infectious disease products mr mcbride brings more than two decades of experience within the canadian pharmaceutical and biotechnology industry his expertise lies in licensing purchasing and divesting assets in addition to advancing the commercialization of early stage assets and identifying opportunities for growth prior to joining appili mr mcbride spent  years at glaxosmithkline inc gsk serving in many roles of increasing responsibility most recently he served as head of an entrepreneurial business unit where he negotiated global asset transactions and was responsible for the commercial success of over  brand assets prior to joining gsk mr mcbride served as a director for healthcare agencies conducting commercial and strategic assessments in both canada and the us and also served as director of marketing with roche pharmaceuticals appili therapeutics inc presents at bloom burton  co sixth annual healthcare investor conference may  pm apr   appili therapeutics inc presents at bloom burton  co sixth annual healthcare investor conference may  pm venue hall b lower concourse level sheraton centre toronto hotel corner of york and queen st west toronto on mh m canada speakers kimberly stephens chief financial officer appili therapeutics inc appoints stephen nicolle to its board of directors jan   appili therapeutics inc announced that stephen nicolle has been appointed to its board of directors mr nicolle has  years of experience leading companies and growing shareholder value he is currently president of cape bear advisors where he consults and holds numerous board positions including vice chair of the startup accelerator propel ict similar private companies by industry company name region  ontario inc americas  ontario inc americas ab biopharma inc americas abcelex technologies inc americas abcellera biologics inc americas recent private companies transactions typedate target private placement december    request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact appili therapeutics inc please visit wwwappilitherapeuticscom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close appili appoints pharmaceutical executive sean mcbride as vice president business development employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       appili appoints pharmaceutical executive sean mcbride as vice president business development tweet   am   life sciences jobs     bullet newest jobs  last  hours   bullet california jobs   bullet massachusetts jobs   bullet new jersey jobs   bullet maryland jobs   bullet washington jobs   view more jobs halifax nova scotiabusiness wireappili therapeutics inc “appili” an antiinfective drug development company announced today that sean mcbride a  year pharmaceutical veteran has joined the company as vice president business development mr mcbride will lead appili’s outlicensing product inlicensing and acquisition opportunities as the company builds its pipeline of infectious disease products we are delighted to have mr mcbride join our strong leadership team” said kevin sullivan ceo of appili therapeutics “sean’s experience in international dealmaking along with his expertise in pharmaceutical sales and marketing will be invaluable as we build our balancedrisk pipeline of neartorevenue opportunities with higherrisk transformational drugs that can truly change the way we treat infectious disease” “this is an exciting time to be joining the appili team as it seeks to take advantage of the many incentives aimed at fighting antibiotic resistance and grow its pipeline of antiinfectives” said mr mcbride “there are many players including government nonprofit and forprofit organizations with an interest in infectious diseases and i look forward to bringing my experience working with these organizations and contributing to the company’s future success” mr mcbride brings more than two decades of experience within the canadian pharmaceutical and biotechnology industry his expertise lies in licensing purchasing and divesting assets in addition to advancing the commercialization of early stage assets and identifying opportunities for growth prior to joining appili mr mcbride spent  years at glaxosmithkline inc gsk serving in many roles of increasing responsibility most recently he served as head of an entrepreneurial business unit where he negotiated global asset transactions and was responsible for the commercial success of over  brand assets prior to joining gsk mr mcbride served as a director for healthcare agencies conducting commercial and strategic assessments in both canada and the us and also served as director of marketing with roche pharmaceuticals mr mcbride has a bachelor of business administration from simon fraser university about appili therapeuticsappili is dedicated to identifying acquiring and advancing novel therapeutics for infectious disease the company has two antiinfective programs ati and ati in its pipeline ati is a tastemasked treatment for anaerobic infections that has been granted orphan drug status by the fda appili plans to take ati into clinical trials in  appili’s second product ati is a novel antibiotic with broad potential to treat deadly gramnegative infections these drugresistant infections have been identified by the us centers for disease control cdc and the world health organization as posing the highest threat to human health for more information visit wwwappilitherapeuticscom appili therapeuticsmedia relationsjennifer cameron mediaappilitherapeuticscomorinvestor relationskevin sullivanceoinfoappilitherapeuticscom read at biospacecom related news appili receives funding from the government of canada to support development of new antibiotic to treat gramnegative infections court papers reveal astrazeneca plc azn ceo was livid over proteges defection to glaxosmithkline gsk appili awarded m from acoa to fund clinical trials sarepta srpt taps allergan agn alum as new ceo appili raises m in equity capital to develop its antiinfective pipeline survey says here are the  mostliked life science ceos appili appoints industry veteran stephen nicolle to its board mylan myl shareholders balk at executive pay package but reelects board despite epipen scandal appili appoints industry veteran stephen nicolle to its board meet the rock star of science obsessed with stopping alzheimers please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • appilitherapeutics   • biotechpharma  personnel                 appili therapeutics inc appoints pharmaceutical executive sean mcbride as vice president business development  business wire appili therapeutics inc appoints pharmaceutical executive sean mcbride as vice president business development july    am eastern daylight time halifax nova scotiabusiness wireappili therapeutics inc “appili” an antiinfective drug development company announced today that sean mcbride a  year pharmaceutical veteran has joined the company as vice president business development mr mcbride will lead appili’s outlicensing product inlicensing and acquisition opportunities as the company builds its pipeline of infectious disease products we are delighted to have mr mcbride join our strong leadership team” said kevin sullivan ceo of appili therapeutics “sean’s experience in international dealmaking along with his expertise in pharmaceutical sales and marketing will be invaluable as we build our balancedrisk pipeline of neartorevenue opportunities with higherrisk transformational drugs that can truly change the way we treat infectious disease” “this is an exciting time to be joining the appili team as it seeks to take advantage of the many incentives aimed at fighting antibiotic resistance and grow its pipeline of antiinfectives” said mr mcbride “there are many players including government nonprofit and forprofit organizations with an interest in infectious diseases and i look forward to bringing my experience working with these organizations and contributing to the company’s future success” mr mcbride brings more than two decades of experience within the canadian pharmaceutical and biotechnology industry his expertise lies in licensing purchasing and divesting assets in addition to advancing the commercialization of early stage assets and identifying opportunities for growth prior to joining appili mr mcbride spent  years at glaxosmithkline inc gsk serving in many roles of increasing responsibility most recently he served as head of an entrepreneurial business unit where he negotiated global asset transactions and was responsible for the commercial success of over  brand assets prior to joining gsk mr mcbride served as a director for healthcare agencies conducting commercial and strategic assessments in both canada and the us and also served as director of marketing with roche pharmaceuticals mr mcbride has a bachelor of business administration from simon fraser university about appili therapeuticsappili is dedicated to identifying acquiring and advancing novel therapeutics for infectious disease the company has two antiinfective programs ati and ati in its pipeline ati is a tastemasked treatment for anaerobic infections that has been granted orphan drug status by the fda appili plans to take ati into clinical trials in  appili’s second product ati is a novel antibiotic with broad potential to treat deadly gramnegative infections these drugresistant infections have been identified by the us centers for disease control cdc and the world health organization as posing the highest threat to human health for more information visit wwwappilitherapeuticscom contacts appili therapeuticsmedia relationsjennifer cameron mediaappilitherapeuticscomorinvestor relationskevin sullivanceoinfoappilitherapeuticscom release summary appili therapeutics inc appoints pharmaceutical executive sean mcbride as vice president business development hashtags antibiotics kevinsullivan amr runningoutoftreatmentoptions startup infectiousdisease nrc superbug businessdevelopment seanmcbride nightmareinfections antimicrobial busdev newantibioticclass appili antibioticresistance drugresistance governmentfunding gramnegative cdcurgent balancedrisk klebsiella biopharma appilitherapeutics orphandrug companygrowth social media profiles appili therapeutics on twitter appili therapeutics on linkedin contacts appili therapeuticsmedia relationsjennifer cameron mediaappilitherapeuticscomorinvestor relationskevin sullivanceoinfoappilitherapeuticscom search advanced news search advanced news search log in sign up appili therapeutics inc appoints kimberly stephens as chief financial officer  business wire appili therapeutics inc appoints kimberly stephens as chief financial officer october    am eastern daylight time halifax nova scotiabusiness wireappili therapeutics inc an antiinfective pharmaceutical development company announced today that kimberly stephens cpa has joined the company as chief financial officer ms stephens will be providing key financial and operational leadership to appili to help drive its growth we are pleased to welcome ms stephens to the appili executive management team” said kevin sullivan ceo of appili therapeutics “her significant financial expertise and insight into the biopharmaceutical industry will bolster our growing scientific pipeline as we take our first product a tastemasked treatment for clostridium difficile infection into clinical trials” “with our first clinical trial on the horizon it’s an exciting time to be joining appili and i look forward to being a key contributor to the company’s future growth and acquisition success” said ms stephens “i am impressed by appili’s strategic focus on treating infectious diseases and it is my privilege to join such a dynamic team of dedicated professionals” ms stephens brings over  years of financial management experience in senior financial positions with private and public companies most recently she served as cfo of immunovaccine inc tsximv otcqximmvf from  where she managed the raising of more than  million through equity financings and government grants prior to joining immunovaccine inc ms stephens served as director of finance for the canadian subsidiary of germanischer lloyd she has also been the director of finance for solutioninc and started her career as an audit manager in the assurance and advisory group at pwc ms stephens holds a bachelor of commerce degree from mount allison university and is a chartered professional accountant cpa ms stephens will continue to serve immunovaccine as chief financial officer through december  while the company conducts its ongoing process of identifying and transitioning her successor about appili therapeutics appili is dedicated to identifying acquiring and advancing novel therapeutics for infectious disease the company has two antiinfective programs ati and ati in its pipeline ati a tastemasked treatment for clostridium difficile infection has been granted orphan drug designation by the fda appili plans to take ati into clinical trials in  appili’s second product ati is a novel antibiotic with broad potential to treat deadly gramnegative infections such as klebsiella pneumoniae these drugresistant infections have been identified by the us center for disease control cdc as posing the highest threat to human health for more information visit wwwappilitherapeuticscom contacts appili therapeuticsmedia relationsjennifer cameron mediaappilitherapeuticscomorinvestor relationskevin sullivanceoinfoappilitherapeuticscom release summary appili appoints kimberly stephens as new chief financial officer hashtags companygrowth cfo kimberlystephens infectiousdisease acoa bloomburton klebsiella drugresistance antibiotics nightmareinfections appilitherapeutics orphandrug superbug kevinsullivan innovacorp newcfo biopharma newantibioticclass appili gramnegative cdcurgent nrcirap cdifficile startup cashtags imv social media profiles appili welcomes new cfo appili appoints new cfo contacts appili therapeuticsmedia relationsjennifer cameron mediaappilitherapeuticscomorinvestor relationskevin sullivanceoinfoappilitherapeuticscom search advanced news search advanced news search log in sign up appili therapeutics inc appoints pharmaceutical executive sean mcbride as vice president business development  news press release  pharmiwebcom navigation accesskey  content accesskey  site search accesskey  job seekers login accesskey  top of page accesskey  go to pharmiweb solutions login  register select a companyabbott diabetes careabbott laboratoriesaccelsiorsaccord healthcareaci group ltd  allchem pharmaactelion pharmaceuticals ltdad instrumentsadallen pharmaadamas consultingaddex pharmaceuticals adds advanced drug development servicesadecco group uk  irelandadelphi groupadvance recruitmentadvanced clinical recruitment ltdadvanced medical solutionsadvanced regulatory uk  europeadvanced ss medical  clinicaladvanced ss usaaerotek allegis group ltdaesica pharmaceuticals limitedaffinity group limitedaffinity group limitedagenda resource managementajilon pharmaakos ltdaktor interactivealconalexander mann servicesalimera sciences limitedallander noble limitedallergan incallergy therapeutics ltdallianz worldwide carealmacalnylam pharmaceuticalsalto marketing limitedaltranamarisamoria bondanglo technical recruitmentanthony nolanantisoma research laboratories ao foundationapex international recruitment ltdapplied driving techniquesaqdotsarcher mathiesonarchimedes pharmaargyll scottarmstrong craven ltdasa medicalashfield healthcare communicationsashfield infocus ltdaspen globalaspire resourcing ltdaspirion pharmaassociation for clinical data managementassociation of clinical research professionalsassociation of clinical research professionalsastbury marsdenastellas qaastralisastrazenecaastrazenecaastrazenecaastrazeneca commercialatom recruitmentaustin fraser limitedaverion international switzerland ltdaverion international corpaxessaxon neuroscience crm services sebaron crawford searchbarrington james clinicalbarrington james europebarrington james medical  executivebarrington james scientificbarts  the london school of medicine  dentistrybarts and the london nhs trustbarts health nhs trustbasecasebausch  lombbayerbayer plcbbi groupbdberesford blake thomasberwick partnersbicycle therapeutics limitedbio products laboratorybio products laboratory limitedbiokinetic europe ltdbioclinicabioenvision ltdbiogen idecbiogen idec international gmbhbiomarin europe limitedbiomedical systemsbiomedical systemsbiorole scientific solutionsbiotronik agbioviabioxydynbiz recruitmentblue pelican pharmabluewavebmj groupbms sales specialists llpboc gases  uk microcylindersboehringer ingelheim schweiz gmbhboehringer ingelheim gmbhboehringer ingelheim pharma gmbh  co kgbootsbounty uk limitedboyden francebreast cancer nowbrecon pharmaceuticals ltdbridgehead internationalbristol myers squibbbritish biocell bth recruitmentbusiness swedencc group holdings ltdcalderdale  huddersfield nhs foundation trustcalderdale and huddersfield nhs foundation trustcaleacambridge regulatory services ltdcamris internationalcancer research ukcancer research uk  ucl cancer trials centre candour recruitmentcandy recruitmentcapita resourcingcardinal healthcardiome pharma corpcarl zeisscatalent pharma solutionscatalent pharma solutionscatenoncatenon iberia saucca  limitedccibccm healthcare ltd ukcdc solutionscelgene international sarlcelgene ltdcelltechcenduitcentre for international migration and developmentchameleon international search ltdcharles river laboratoriescharterhousechasechilternchironchiron vaccinescircassia limitedcircassia pharmaceuticalscis life sciencescititec associates limitedcity of london group plcck clinicalclark james limitedclay mcguireclearwater people solutionsclinical network services pty ltdclinical professionals ltdclinical trials victoria limitedclinipace worldwide was paragon biomedicalclinipace worldwide was paragon biomedicalclinipace worldwide was paragon biomedicalclinphoneclinsys clinical researchclinteccloud nine recruitment solutions ltdcluepoints sacmed group ltdcognitive drug research ltdcognitive drug research ltdcognizant technology solutions uk ltdcognolink ltd cogstate ltdconcordiaconstares gmbhcontact singaporecorbioncordiscorelab partners inccovancecplcpl recruitment  science  cpl resources plccrccrf health management ltdcriticaltalent limitedcrofessionals llccromedicacromsourcecromsourcecslcsl behringcsl limitedcsl limited csl limitedcsl recruitmentctc resourcing solutionscti clinical trial and consulting servicescti clinical trial and consulting servicescurium pharmacustom clinical solutionscustom interconnect ltdcyteldabur oncologydaiichi sankyodaiichi sankyo uk ltddanisco sweeteners oy  dupont nutrition  healthdanonedatamonitordatatrial ltddcz life science personalmanagement gmbhddr jobsde verchin  partnersdecision resources international incdecode geneticsdefence science and technology laboratorydelphic diagnosticsderks  derks bvdermal laboratoriesdevrodiamond light source ltddignity sciencesdndidndidocs globaldocs global continental europedokumedsdolon ltddr reddysdrug safety peopleeamesjonesjudgehawkingseasthornebsco publishingedelway switzerland ageden scottedqmedqm council of europeef medicaleirx therapeutics ltdeisai europe ltdeisai london research laboratories limitedelaine coyleelan computing schweiz agelan itelevate direct ltdeli lillyeli lillyeli lilly and companyeli lilly and company ltdeli lilly contractsemsearch search and selectionendpoint research enhance people consultantsenhancing ltdentrust resourcing solutionsenvalisenvigoepm scientificeprofile pharma consultants sarlergon resourcesesiftethical medicines industry groupeupraxia pharmaceuticals inceuromedicaeuropean clinical research infrastructure networkeuropean patent officeeuropitaleuropital eusa pharmaevaluatepharma ltdevidenciaevideraevolution consultantsevolve selectionevotecewi recruitmentexcel communicationsexcellion bvexcelya sasexecutives onlineexemplar peopleexemplar peopleexperisf hoffmannla roche agfacilitate ltdfagron uk ltdfal duivenbvfarillonfforde managementfideltafindfindersfisher clinicalflame pharmafood standards agencyfr europefrazer jonesfreedom life sciencesfresenius kabifresenius kabifulcrum pharmafulcrum pharma europe ltdfulcrum pharma europe ltdfutures clinicalfutures executivefutures resourcingfutures salesfuturestep uk ltdgalderma uk ltdgalderma rdgalloway jones consultinggalpharm internationalgavi alliancegce solutionsgenea biomedxgenentechgenentechgenericsweb ltdgenmab ltdgenomic healthgenomics englandgenzyme ltdgenzyme therapeuticsgeorge clinicalgerd schierenberg search  selection gmbhgerson lehrman groupgetingegfk bridgeheadgilead sciencesglaxosmithklineglaxosmithkline plcglenmark generics europe ltdglenmark pharmaceuticalsglenmark pharmaceuticals saglobe life sciencesglycotope gmbhgold groupgrafton recruitmentgreen park contentgreythorngrunenthal ltdgskgskgw pharmaceuticalsgw pharmaceuticalsgw pharmaceuticals plchal allergy grouphales and hindmarsh associates ltdhammersmith medicines research ltdharvey nash aghayburyhays bvhays healthcare hays life scienceshc solutions uk ltdhealth decisionshealthcare at homehealthcare communications associationhealthcare technology internationalheronhmg worldwidehobson priorhodes healthcarehoggett bowershollister limitedhospira adelaide pty ltdhospira uk ltdhr dynamics hudsonhudson shribman scientific recruitmenthumanicshumanvaluehunter macdonald ltdhuntingdon life sciences ltdhuntress grouphvivo plchypha discovery ltdipharm consultingibcsg international breast cancer study groupicardiac technologies incicon clinical researchicon development solutions icon plcicrg ltdid search  selectionidisidox tfplids ukiir conferencesimanova ltdimmucorimmunocore ltdimmunodiagnostic systemsimperial college londonimperial college londonimperial college londonims healthinc researchincrom europeindex pharmaceuticalindigomedicalinharmony gmbh innopharma srlinnovenninpharmation ltdinpharmation ltdinstitut jules bordet ijbinstitute for oneworld healthinstitute of cancer researchinstitute of clinical researchintercept pharmainternational centre for neurotherapeuticsintum ltdinventiv health clinicalinvivodata incirbm istituto di ricerche di biologia molecolare isis recruitment solutions ltditc pharmaiti life sciencesits pharmaixicojakob  partnersjanssen pharmaceuticajanssencilagjanssencilag ltdjcw life sciencesjobboxx executive searchjohnson  johnson medicaljohnson  johnson seincjoint clinical trials officekings college londonjuice resource solutionsjust pharmajust retirementkcr sakd consulting search  selectionkdc group kelly  king associates ltdkelly serviceskendlekendle internationalkenexakey people limitedkeyrus biopharmakienbaum executive consultantskienbaum executive consultantskienbaum executive searchkings health partners clinical trials officekings collegekingston general hospitalkirkham young ltdknow how recruitmentkoenigsteiner agenturkowa research europe ltdkubo recruitmentkuowa executive searchkyowa kirin international plclaser europe ltdlaser gmbhlaser grouplab supportlanglandlcg bioscienceleeds institute of health sciencesleica microsystems leiden university medical centre lfblife scanlife science consultants ltdlife science dynamicslife scientificlife technologieslifecycle marketing ltdlinde healthcare the linde group linical europe gmbhlinical spainliquentliverpool school of tropical medicinelloyds pharmacylongbridge international plclonza biologics plcludger ltdlupin europe limitedlymphoma associationmtagmalvern instrumentsmanagement forummanor executive searchmapi consultancymapi groupmapi valuesmarie stopes internationalmarix drug development limitedmarketplace technicalmarks sattinmartindale pharmamatchtech groupmatrix evidencemayne manufacturing solutionsmayne pharmamba intelligent solutionsmcguire global recruitment mci groupmdgroupmeadwestvacomediatum gmbhmedicines evaluation unitmedicines patent poolmedicor globalmedidata solutions incmedikidz limitedmedikidz ltdmedimmunemeditech mediameditech mediamedochemiemedochemie ltdmedpacemedpass international ltdmedscapemedsci healthcare communicationsmeetmerckmerck kgaamerck research laboratories italymerck serono sa  geneva merck serono ukmercuri urvalmercuri urval ltdmercury pharmamesmmhramichael page internationalmicromet ag mid cheshire hospitals nhs trustmiddleton jeffers recruitment ltdmikes test companymillward brown uk ltdmms holdings incmologen agmonitor monitoring force moorfields eye hospitalmoorfields pharmaceuticalsmoorfields pharmaceuticalsmorecambe bay hospitals nhs trustmorgan jonesmorgan keatingmorgan levymorgan philips executive searchmorgan prestwich pharmaceutical recruitmentmosaic regulatory solutionsmsdmsi group limitedmundipharma international limited mundipharma research ltdmurex biotech limitedmwv services austria gmghmylanmylan pharma uknamsanature communicationsnemaura pharmaneolab limitednestlé nestlé sanetwork jobsnetwork recruitmentnewcastle universitynhs blood  transplant  nhsbtnhs blood and transplantnhs innovations londonnicenicholas howardnorginenorth bristol nhs trustnorth point recruitmentnorthwest ehealthnovartisnovartisnovartis pharma agnovella clinical resourcingnovelle lynchnovo nordisk novo nordisknovocure gmbhnucleus centralnutricia limitednutricia ltdnuvisan clinical development solutions oldobsevaobvious solutions ltdochre houseocs consulting ltdoctodgers selectolea consultingoncall llconcore ukonline resourcingonly medics recruitment ltdono pharma uk ltdoptima searchoptimus search limitedoptuminsightoracle health sciencesorchard therapeuticsorganisation for the prohibition of chemical weapoorion clinical servicesortho biotechorthoclinical diagnosticsoryzon genomics otsuka frankfurt research institute gmbh outcomeoxford biomedica uk limitedoxford biomedica uk limitedoxford pharmagenesisoxford universityoxford university innovationoxitec limitedoxygen life science solutionspackaging coordinators incpage executivepanacea pharma projects ltdparexelparkacre enterprises ltdpathpatheon austria gmbh  co kgpdr partnerspenn pharmapeoplescoutpersoneelsadviesbureau goelenpfizerpfizer incpfizer nutrition ph associates ltdpharmolam internationalpharma consulting grouppharma marpharmadirect uk  europe ltdpharmaceutical  medical professionalspharmaceutical profilespharmalink consultingpharmalys ltdpharmareview ltdpharmarspharmasciencepharmaseekpharmiweb recruitmentpharmiweb solutionspharos ltdphilip chapper  company ltdphilip morris international management saphlexglobalphlexglobalpierrel research europe gmbhpierrel research europe gmbhplanet pharma staffing limitedplethora solutions limted plusprojectplymouth hospitals nhs trustpoise consulting ltdpop science limitedppdpra health sciencespreglempremier researchpricespective llcpricewaterhousecoopers llpprime pharmaprimevigilance primoris contract solutionsprma consulting ltdprn recruitmentproclinical ltdproductlife ltd formerly verius ltdprofessional careers consulting pcc ltdprogressive recruitmentprogressive recruitment germanypropagate propharma solutionsproscape technologiesprostrakan limitedprotexinpsi cro ltdpsi cro uk ltdpsi cro uk ltdpsr grouppsr group bvpsr pharma resourcepurinaqmaticquanticatequeen anne street medical centre quest resourcing ltdquintilesquintiles hungary ltd quintiles magyarország kftquotient bioresearchquotient clinicalquotient clinical ltdraftrainford berry limited random medical animationrayner intraocular lenses ltdrbw consultingrdl scientificreading scientific services ltdreal hr solutions real life sciencesreal life sciences germanyreal life sciences switzerlandreckitt benckiserrecruitmentrecruitment plusrecruitmentgeniusreed scientificregulatory professionalsregulis consultingrenovoresearch review recruitrespiratory effectiveness groupretrogenixrichmond pharmacologyrising tide gmbhrm it professional resources agrmgrnidrobarts clinical trials rocheroche diagnostics limitedroyal chemistry societyroyal free hospital hampsteadroyal liverpool  broadgreen university hospitalsroyal united hospital bathrpslrsa consulting gmbhrti health solutionsrushworth associates limitedruston poole intruston poole internationalscubed limitedsandoz biopharmaceuticalssankyo pharmasanofisb consultingscaschering health carescinopsissciprosck•censearch consultancysearch scientificsec recruitmentselborne biological services ltdselciaseltek consultantssentinelseqirus ltdseqirus ltdservierseven life sciencessharp clinical services uk ltdshire pharmaceuticalssiemens healthcare diagnosticssiemens medical solutions petnet solutionssigma aldrich corporationsigma recruitment ltdsigmar recruitment sp zoosignet resourcessimbec orion group ltdskills alliancesla pharma uk ltdsls servicessmerud medical research uk ltdsmith  nephew medicalsmith  nephew medical ltdsobisolvay healthcarespectrum regulatory solutionsspectrum regulatory solutions ltdspirax sarcospotted limited division jacobsen havelock woodspringer healthcare ltdsquare one pharmasquarepeg recruitment solutions ltdsra global clinical developmentsrg clinicalsrg interesourcesrl pharmaceuticalsssafast andrewsstamford consultantsstarstem med pte ltdsterling hr consultingsth nhs foundation truststhree management services ltdstiefel laboratories succinct healthcare communicationsswanstaff recruitment ltdswift selectionsymmetron ltdsynapse medical resourcing limitedsynarcsynarcsynarc incsynarc ltdsynchrogenix information strategies incsynchrogenix information strategies incsynergy visionsynexus limitedsynovate healthcaresynteracthcr deutschland gmbhsyreon corporationsyreon corporationsyreon corporationtakeda development centre europetalentmarktalentmark search  selectiontalisman software satardis medical consultancytaylor and francis grouptc biopharmtec group internationaltempleton recruitmentteva uk limitedtfs trial form support internationaltfs trial form support llctfs trial form support ltdthe christie nhs foundation the general pharmaceutical councilthe health protection agency hpa the institute of cancer researchthe leeds teaching hospitals nhs trustthe london clinicthe martin veasey partnershipthe medicines companythe nihr biomedical research centrethe rft groupthe science and technology facilities council the spencer groupthe spencer group ltdthe university of edinburgh theorem clinical researchtheorem clinical research was omnicaretheradex europe ltdthermo fisher scientificthermo scientific was remel europethirtythreethomson reutersthomson scientificthornshaw recruitmentthornton and ross limitedtmc pharma limitedtmp worldwidetower mains quality assurance tmqatpp recruitmenttransparency international uktrm oncology bvtrue north human capital ltdturner regulatoryubm medica ltduc davis health systemuc davis health systemucbuclunileverunited biosource corporationuniversity hospital bristoluniversity hospital of south manchesteruniversity of bristoluniversity of dundeeuniversity of durhamuniversity of hertfordshireuniversity of newcastle upon tyneuniversity of oxforduniversity of oxforduniversity of oxford  department of oncologyuniversity of sheffield university of southamptonuniversity of southampton clinical trials unituniversity of surreyuptodatevacancy management companyvalidantvantage recruitment solutions ltdvecturaveeda clinical research ltdvegenatvenn kinesisvenn life sciencesventana medical systemsverius ltdvertex pharmaceuticals europe limitedviiv healthcarevirdis groupvita green pharmaceutical hk ltdvoisin consulting life sciencesvrs regulatoryvsowacker chemie agwainwright associates limitedwebsearch recruitment ltdwentworth pharmaceuticalwhipps cross university hospital nhs trustwhitehall internationalwhitehead mannwilson alexander ltdwockhardt woodhurstworld class international wciworldwide clinical trialsworthing and southlands hospitals nhs trustx groupzeincro hellas sazest scientificzimmer biomet pharmiweb channelsall  pharmaco  clinical research  rdbiotech  salesmktg  healthcare  recruitment  pharmacy  medical comms home news show all pharmaco clinical research rd  biotech sales  mktg healthcare recruitment pharmacy medical comms resources pharmiweb today features press releases events job search handbook previous polls free personality test newsletter archive link directory editorial calendar company login events webinars courses other jobsearch job search executive jobs entry level pharma jobs auditor jobs biostatistics jobs brand manager jobs business development jobs clinical data manager jobs clinical project manager jobs cra jobs compliance jobs drug safety jobs feasibility jobs health economics jobs liaison jobs marketing jobs medical affairs jobs medical advisor jobs medical device sales jobs medical information jobs medical rep jobs medical writing jobs nurse  nursing jobs pharmaceutical marketing jobs pharmaceutical sales jobs pharmacist jobs pharmacovigilance jobs product manager jobs project management jobs qaqcquality jobs recruitment jobs regulatory jobs regulatory affairs jobs sales jobs sas programmer jobs statistics jobs study manager jobs companies show all pharmaco clinical research rdbiotech salesmktg healthcare recruitment pharmacy medical comms how to get a job using pharmiwebcom write a better cv write a covering letter get job as a medical sales rep give a leaving speech pass personality tests enter the cyberspace recruitment market cope with redundancy get past the receptionist get shadowing experience about us contact us jobs currently  jobs jobs in the uk jobs in europe jobs in usa jobs in asia global jobs candidates login sign in forgotten details cv database let the jobs come to you sign up company login account login open an account site newsletter sign up for the pharmiwebcom newsletter pharmiwebcom rss feeds pharmiweb candidate blog pharmiweb client blog pharmiweb on facebook advertising press release submit a press release send this to a friend go back to listappili therapeutics inc appoints pharmaceutical executive sean mcbride as vice president business developmentappili therapeuticsposted on  jul more appili therapeutics press releases appili therapeutics inc “appili” an antiinfective drug development company announced today that sean mcbride a  year pharmaceutical veteran has joined the company as vice president business development mr mcbride will lead appili’s outlicensing product inlicensing and acquisition opportunities as the company builds its pipeline of infectious disease products we are delighted to have mr mcbride join our strong leadership team” said kevin sullivan ceo of appili therapeutics “sean’s experience in international dealmaking along with his expertise in pharmaceutical sales and marketing will be invaluable as we build our balancedrisk pipeline of neartorevenue opportunities with higherrisk transformational drugs that can truly change the way we treat infectious disease” “this is an exciting time to be joining the appili team as it seeks to take advantage of the many incentives aimed at fighting antibiotic resistance and grow its pipeline of antiinfectives” said mr mcbride “there are many players including government nonprofit and forprofit organizations with an interest in infectious diseases and i look forward to bringing my experience working with these organizations and contributing to the company’s future success” mr mcbride brings more than two decades of experience within the canadian pharmaceutical and biotechnology industry his expertise lies in licensing purchasing and divesting assets in addition to advancing the commercialization of early stage assets and identifying opportunities for growth prior to joining appili mr mcbride spent  years at glaxosmithkline inc gsk serving in many roles of increasing responsibility most recently he served as head of an entrepreneurial business unit where he negotiated global asset transactions and was responsible for the commercial success of over  brand assets prior to joining gsk mr mcbride served as a director for healthcare agencies conducting commercial and strategic assessments in both canada and the us and also served as director of marketing with roche pharmaceuticals mr mcbride has a bachelor of business administration from simon fraser university about appili therapeutics appili is dedicated to identifying acquiring and advancing novel therapeutics for infectious disease the company has two antiinfective programs ati and ati in its pipeline ati is a tastemasked treatment for anaerobic infections that has been granted orphan drug status by the fda appili plans to take ati into clinical trials in  appili’s second product ati is a novel antibiotic with broad potential to treat deadly gramnegative infections these drugresistant infections have been identified by the us centers for disease control cdc and the world health organizationas posing the highest threat to human health for more information visit wwwappilitherapeuticscom view source version on businesswirecom httpwwwbusinesswirecomnewshomeen business wirewwwbusinesswirecomlast updated on  subscribe in a reader send this to a friend key   required field your friends email your email enter your comment here if any human verification  advertising share    site map  privacy  security  cookies  terms and conditions pharmiwebcom is europes leading industrysponsored portal for the pharmaceutical sector providing the latest jobs news features and events listings the information provided on pharmiwebcom is designed to support not replace the relationship that exists between a patientsite visitor and hisher physician appili therapeutics infoappilitherapeutics ext    appili therapeutics bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one